

**What is Chiasma's patent position on MYCAPSSA?**

Chiasma believes it has a strong U.S. and E.U. patent position, including an issued MYCAPSSA formulation patent that expires in late 2029 and an issued U.S. dosing patent application that expires in early 2036. The submission for a dose titration patent in the E.U. is pending.

MYCAPSSA was granted orphan drug designation in the U.S. and E.U. and Chiasma is seeking orphan drug exclusivity for MYCAPSSA in the U.S. However, the final exclusivity determination will be made by FDA and there can be no assurances that the FDA will grant such exclusivity. Chiasma plans to provide an update on U.S. orphan status following FDA's decision.

Dated: June 26, 2020